These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 9691110

  • 1. Treatment of Crohn's disease at the turn of the century.
    Bickston SJ, Cominelli F.
    N Engl J Med; 1998 Aug 06; 339(6):401-2. PubMed ID: 9691110
    [No Abstract] [Full Text] [Related]

  • 2. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E.
    N Engl J Med; 1998 Aug 06; 339(6):370-4. PubMed ID: 9691103
    [Abstract] [Full Text] [Related]

  • 3. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG, Sandborn WJ.
    Rev Gastroenterol Disord; 2002 Aug 06; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [Abstract] [Full Text] [Related]

  • 4. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ, Petraki K, Sfakianakis M, Archavlis E, Christidou A, Chadio-Iordanides H, Triadaphyllou G.
    Clin Gastroenterol Hepatol; 2003 Mar 06; 1(2):122-8. PubMed ID: 15017504
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Drug therapy of Crohn disease].
    Niemelä S.
    Duodecim; 2001 Mar 06; 117(8):807-14. PubMed ID: 12116446
    [No Abstract] [Full Text] [Related]

  • 7. Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease.
    Rutgeerts P.
    Gut; 1999 Jul 06; 45(1):13-4. PubMed ID: 10498451
    [No Abstract] [Full Text] [Related]

  • 8. [Drug therapy of inflammatory bowel diseases].
    Silvennoinen J, Niemelä S.
    Duodecim; 1999 Jul 06; 115(20):2233-8. PubMed ID: 11973927
    [No Abstract] [Full Text] [Related]

  • 9. Algorithm for the treatment of Crohn's disease: incorporation of emerging therapies.
    Souney PF.
    Am J Gastroenterol; 2000 Sep 06; 95(9):2381-3. PubMed ID: 11007248
    [No Abstract] [Full Text] [Related]

  • 10. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E, International Budesonide-Mesalazine Study Group.
    Am J Gastroenterol; 2002 Mar 06; 97(3):649-53. PubMed ID: 11922560
    [Abstract] [Full Text] [Related]

  • 11. [New therapeutic modalities in Crohn's disease].
    Rachmilewitz D.
    Harefuah; 1999 Jun 15; 136(12):943-5. PubMed ID: 10955155
    [No Abstract] [Full Text] [Related]

  • 12. [Paradigmatic shift in drug treatment of Crohn disease].
    Munck LK.
    Ugeskr Laeger; 2005 Aug 15; 167(33):3013. PubMed ID: 16109239
    [No Abstract] [Full Text] [Related]

  • 13. A comparison of budesonide and mesalamine for active Crohn's disease.
    Lowry PW, Sandborn WJ.
    Gastroenterology; 1999 May 15; 116(5):1263. PubMed ID: 10220523
    [No Abstract] [Full Text] [Related]

  • 14. Budesonide modified-release capsules.
    Baker DE.
    Rev Gastroenterol Disord; 2001 May 15; 1(3):147-55. PubMed ID: 12120182
    [Abstract] [Full Text] [Related]

  • 15. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
    MMW Fortschr Med; 2009 May 07; 151(19):38-9. PubMed ID: 19827443
    [No Abstract] [Full Text] [Related]

  • 16. The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease.
    Rutgeerts P.
    Mediators Inflamm; 1998 May 07; 7(3):137-40. PubMed ID: 9705597
    [Abstract] [Full Text] [Related]

  • 17. [Drug therapy of Crohn's disease: slowly increase or start aggressively right away?].
    Bischoff A.
    MMW Fortschr Med; 2010 Jan 14; 152(1-2):20. PubMed ID: 20302159
    [No Abstract] [Full Text] [Related]

  • 18. [Maintaining a remission].
    Fleig WE, German Society for Digestive and Metabolic Diseases.
    Z Gastroenterol; 2003 Jan 14; 41(1):36-42. PubMed ID: 12541172
    [No Abstract] [Full Text] [Related]

  • 19. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
    Sandborn WJ, Feagan BG.
    Aliment Pharmacol Ther; 2003 Aug 01; 18(3):263-77. PubMed ID: 12895211
    [Abstract] [Full Text] [Related]

  • 20. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
    Feagan BG.
    Eur J Surg; 1998 Dec 01; 164(12):903-9. PubMed ID: 10029385
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.